Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells

被引：31

作者：

Yu, Xinyi ^{[1
,2
,3
,4
,5
,6
,7
]}

Liu, Feng ^{[7
,8
]}

Zeng, Liyi ^{[7
,9
,10
]}

He, Fang ^{[1
,2
,3
,4
,5
,6
,7
]}

Zhang, Ruyi ^{[7
,11
,12
]}

Yan, Shujuan ^{[7
,11
,12
]}

Zeng, Zongyue ^{[7
,11
,12
]}

Shu, Yi ^{[7
,8
,11
,12
]}

Zhao, Chen ^{[1
,2
,3
,4
,5
,6
,7
]}

Wu, Xingye ^{[1
,2
,3
,4
,5
,6
,7
]}

Lei, Jiayan ^{[1
,2
,3
,4
,5
,6
,7
]}

Zhang, Wenwen ^{[7
,13
]}

Yang, Chao ^{[7
,8
]}

Wu, Ke ^{[7
,8
]}

Wu, Ying ^{[7
,14
]}

An, Liping ^{[7
,15
,16
]}

Huang, Shifeng ^{[1
,2
,3
,4
,5
,6
,7
]}

Ji, Xiaojuan ^{[7
,8
]}

Gong, Cheng ^{[7
,17
]}

Yuan, Chengfu ^{[7
,18
]}

Zhang, Linghuan ^{[7
,8
]}

Feng, Yixiao ^{[1
,2
,3
,4
,5
,6
,7
]}

Huang, Bo ^{[7
,9
,10
,19
]}

Liu, Wei ^{[1
,2
,3
,4
,5
,6
,7
]}

Zhang, Bo ^{[7
,15
,16
]}

Dai, Zhengyu ^{[7
,20
]}

Wang, Xi ^{[7
,11
,12
]}

Liu, Bo ^{[1
,2
,3
,4
,5
,6
,7
]}

Haydon, Rex C. ^{[7
]}

Luu, Hue H. ^{[7
]}

Gan, Hua ^{[1
,2
,3
,4
,5
,6
]}

He, Tong-Chuan ^{[7
]}

Chen, Liqun ^{[1
,2
,3
,4
,5
,6
,7
]}

机构：

[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Nephrol, Chongqing, Peoples R China

[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing, Peoples R China

[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China

[4] Chongqing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Chongqing, Peoples R China

[5] Chongqing Med Univ, Affiliated Hosp 1, Dept Plast Surg, Chongqing, Peoples R China

[6] Chongqing Med Univ, Affiliated Hosp 1, Dept Clin Lab Med, Chongqing, Peoples R China

[7] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA

[8] Chongqing Med Univ, Childrens Hosp, Stem Cell Biol & Therapy Lab, Minist Educ,Key Lab Child Dev & Disorders, Chongqing, Peoples R China

[9] Cent S Univ, Zhuzhou Cent Hosp, Dept Infect Control, Zhuzhou, Peoples R China

[10] Cent S Univ, Xiangya Med Coll, Affiliated Zhuzhou Hosp, Zhuzhou, Peoples R China

[11] Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing, Peoples R China

[12] Chongqing Med Univ, Sch Lab Med, Chongqing, Peoples R China

[13] Chongqing Med Univ, Affiliated Univ Town Hosp, Dept Obstet & Gynecol, Chongqing, Peoples R China

[14] Beijing Univ Chinese Med, Dept Immunol & Microbiol, Beijing, Peoples R China

[15] Lanzhou Univ, Key Lab Orthopaed Surg Gansu Prov, Hosp 2, Lanzhou, Gansu, Peoples R China

[16] Lanzhou Univ, Dept Orthopaed Surg, Hosp 2, Lanzhou, Gansu, Peoples R China

[17] Wuhan Univ, Dept Surg, Zhongnan Hosp, Wuhan, Hubei, Peoples R China

[18] China Three Gorges Univ, Dept Biochem & Mol Biol, Sch Med, Yichang, Peoples R China

[19] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab Med, Nanchang, Jiangxi, Peoples R China

[20] Chongqing Hosp Tradit Chinese Med, Dept Orthopaed Surg, Chongqing, Peoples R China

来源：

CELLULAR PHYSIOLOGY AND BIOCHEMISTRY | 2018年 / 47卷 / 03期

基金：

美国国家卫生研究院;

关键词：

Niclosamide; Renal cell carcinoma; Kidney cancer; Drug repurposing; Metastatic renal cancer; Targeted therapy; HUMAN OSTEOSARCOMA GROWTH; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN PATHWAY; OVARIAN-CANCER; KIDNEY CANCER; STEM-CELLS; RESISTANCE; INHIBITION; THERAPY; DIFFERENTIATION;

D O I：

10.1159/000490140

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Background/Aims: As the most lethal urological cancers, renal cell carcinoma (RCC) comprises a heterogeneous group of cancer with diverse genetic and molecular alterations. There is an unmet clinical need to develop efficacious therapeutics for advanced, metastatic and/or relapsed RCC. Here, we investigate whether anthelmintic drug Niclosamide exhibits anticancer activity and synergizes with targeted therapy Sorafenib in suppressing RCC cell proliferation. Methods: Cell proliferation and migration were assessed by Crystal violet staining, WST-1 assay, cell wounding and cell cycle analysis. Gene expression was assessed by qPCR. In vivo anticancer activity was assessed in xenograft tumor model. Results: We find that Niclosamide effectively inhibits cell proliferation, cell migration and cell cycle progression, and induces apoptosis in human renal cancer cells. Mechanistically, Niclosamide inhibits the expression of C-MYC and E2F1 while inducing the expression of PTEN in RCC cells. Niclosamide is further shown to synergize with Sorafenib in suppressing RCC cell proliferation and survival. In the xenograft tumor model, Niclosamide is shown to effectively inhibit tumor growth and suppress RCC cell proliferation. Conclusions: Niclosamide may be repurposed as a potent anticancer agent, which can potentiate the anticancer activity of the other agents targeting different signaling pathways in the treatment of human RCC. (C) 2018 The Author(s) Published by S. Karger AG, Basel

引用

页码：957 / 971

页数：15

共 50 条

[21] Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
Hiroaki Sugiyama
Kenichiro Onuki
Kazunori Ishige
Nobue Baba
Tetsuya Ueda
Sachiko Matsuda
Kaoru Takeuchi
Masafumi Onodera
Yasuni Nakanuma
Masayuki Yamato
Masakazu Yamamoto
Ichinosuke Hyodo
Junichi Shoda
Journal of Gastroenterology, 2011, 46 : 779 - 789
[22] Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells
Sugiyama, Hiroaki
Onuki, Kenichiro
Ishige, Kazunori
Baba, Nobue
Ueda, Tetsuya
Matsuda, Sachiko
Takeuchi, Kaoru
Onodera, Masafumi
Nakanuma, Yasuni
Yamato, Masayuki
Yamamoto, Masakazu
Hyodo, Ichinosuke
Shoda, Junichi
JOURNAL OF GASTROENTEROLOGY, 2011, 46 (06) : 779 - 789
[23] Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
Okubo, Kazuki
Isono, Makoto
Miyai, Kosuke
Asano, Takako
Sato, Akinori
CANCER SCIENCE, 2020, 111 (01) : 112 - 126
[24] Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells
Yu, Shubin
Wang, Zhongyuan
Su, Zijie
Song, Jiaxing
Zhou, Liang
Sun, Qi
Liu, Shanshan
Li, Shiyue
Li, Ying
Wang, Meina
Zhang, Guo-Qiang
Zhang, Xue
Liu, Zhong-Jian
Lu, Desheng
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2018, 18
[25] Gigantol inhibits Wnt/β-catenin signaling and exhibits anticancer activity in breast cancer cells
Shubin Yu
Zhongyuan Wang
Zijie Su
Jiaxing Song
Liang Zhou
Qi Sun
Shanshan Liu
Shiyue Li
Ying Li
Meina Wang
Guo-Qiang Zhang
Xue Zhang
Zhong-Jian Liu
Desheng Lu
BMC Complementary and Alternative Medicine, 18
[26] Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt/β-catenin signaling
Sun, Qi
Fu, Qiuxia
Li, Shiyue
Li, Junjun
Liu, Shanshan
Wang, Zhongyuan
Su, Zijie
Song, Jiaxing
Lu, Desheng
ONCOLOGY REPORTS, 2019, 42 (05) : 1735 - 1744
[27] The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells
Krepler, Clemens
Chunduru, Srinivas K.
Halloran, Molly B.
He, Xu
Xiao, Min
Vultur, Adina
Villanueva, Jessie
Mitsuuchi, Yasuhiro
Neiman, Eric M.
Benetatos, Christopher
Nathanson, Katherine L.
Amaravadi, Ravi K.
Pehamberger, Hubert
McKinlay, Mark
Herlyn, Meenhard
CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1784 - 1794
[28] Cucurbitacin-I exhibits anticancer activity by inducing apoptosis in SKOV3 human ovarian cancer cells
Park, Ji-Won
Kim, Seong Mi
Lee, Soo Yeon
Park, Seung-Won
Kim, Jin-Kyung
MOLECULAR & CELLULAR TOXICOLOGY, 2025, 21 (01) : 271 - 279
[29] M3, a natural lignan xyloside, exhibits potent anticancer activity in HCT116 cells
Shen, Weidong
Zhao, Yu
Chen, Haijiao
Zhang, Ting
Wu, Shenbao
Liu, Pengfei
ONCOLOGY LETTERS, 2019, 17 (02) : 2117 - 2122
[30] Schisandrin B exhibits potent anticancer activity in triple negative breast cancer by inhibiting STAT3
Dai, Xuanxuan
Yin, Changtian
Guo, Guilong
Zhang, Yi
Zhao, Chenguang
Qian, Jianchang
Wang, Ouchen
Zhang, Xiaohua
Liang, Guang
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 358 : 110 - 119

← 1 2 3 4 5 →